1. Human Fis1 directly interacts with Drp1 in an evolutionarily conserved manner to promote mitochondrial fission.
- Author
-
Nolden KA, Harwig MC, and Hill RB
- Subjects
- Humans, Alanine metabolism, Mitochondria genetics, Mitochondria metabolism, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae metabolism, Dynamins genetics, Dynamins metabolism, Mitochondrial Dynamics, Mitochondrial Proteins metabolism
- Abstract
Mitochondrial fission protein 1 (Fis1) and dynamin-related protein 1 (Drp1) are the only two proteins evolutionarily conserved for mitochondrial fission, and directly interact in Saccharomyces cerevisiae to facilitate membrane scission. However, it remains unclear if a direct interaction is conserved in higher eukaryotes as other Drp1 recruiters, not present in yeast, are known. Using NMR, differential scanning fluorimetry, and microscale thermophoresis, we determined that human Fis1 directly interacts with human Drp1 (K
D = 12-68 μM), and appears to prevent Drp1 assembly, but not GTP hydrolysis. Similar to yeast, the Fis1-Drp1 interaction appears governed by two structural features of Fis1: its N-terminal arm and a conserved surface. Alanine scanning mutagenesis of the arm identified both loss-of-function and gain-of-function alleles with mitochondrial morphologies ranging from highly elongated (N6A) to highly fragmented (E7A), demonstrating a profound ability of Fis1 to govern morphology in human cells. An integrated analysis identified a conserved Fis1 residue, Y76, that upon substitution to alanine, but not phenylalanine, also caused highly fragmented mitochondria. The similar phenotypic effects of the E7A and Y76A substitutions, along with NMR data, support that intramolecular interactions occur between the arm and a conserved surface on Fis1 to promote Drp1-mediated fission as in S. cerevisiae. These findings indicate that some aspects of Drp1-mediated fission in humans derive from direct Fis1-Drp1 interactions that are conserved across eukaryotes., Competing Interests: Conflict of interest R. B. H. and K. A. N. have a financial interest in Cytegen, a company developing therapies to improve mitochondrial function. However, neither the research described herein was supported by Cytegen nor was in collaboration with the company. The other authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF